Key Takeaways
- Oral semaglutide 25mg achieved 14–17% average weight loss over 64 weeks (OASIS-4), matching standard 2.4mg weekly Wegovy injections (15–17% in STEP-1).
- Higher-strength Wegovy 7.2mg (19–21% in STEP UP) and dual-agonist Mounjaro 15mg (20–22.5% in SURMOUNT-1) still deliver the highest overall weight reduction.
- In real-world care, daily fasting adherence on oral semaglutide vs. once-weekly pen convenience often determines individual outcomes.
For years, achieving 15%+ medical weight loss meant self-injecting once a week. Today’s oral GLP-1 tablets — oral semaglutide 25mg (Wegovy pill) and orforglipron (Foundayo) — close much of that gap, though important differences remain at the top of the efficacy spectrum.
Phase 3 clinical trial results side by side
| Treatment & Format | Active Mechanism | Landmark Phase 3 Trial | Average Body-Weight Loss |
|---|---|---|---|
| Foundayo Daily Pill | Small-molecule GLP-1 (orforglipron) | ATTAIN-1 (72 weeks) (2) | ~11%–12% |
| Wegovy Daily Pill (25mg) | Oral peptide GLP-1 (semaglutide) | OASIS-4 (64 weeks) (1) | ~14%–17% |
| Wegovy Weekly Pen (2.4mg) | Injectable GLP-1 (semaglutide) | STEP-1 (68 weeks) (3) | ~15%–17% |
| Wegovy High-Dose Pen (7.2mg) | Injectable GLP-1 (semaglutide) | STEP UP (72 weeks) (4) | ~19%–21% |
| Mounjaro Weekly Pen (15mg) | Dual GIP + GLP-1 (tirzepatide) | SURMOUNT-1 (72 weeks) (5) | ~20%–22.5% |
Why adherence separates trial data from everyday life
Weekly GLP-1 injections deliver predictable bioavailability with a single weekly routine. By contrast, oral semaglutide requires daily morning fasting, ≤120mL of plain water, and a 30-minute wait before coffee or breakfast (6) — skipping those steps sharply lowers drug absorption. Meanwhile, small-molecule orforglipron removes fasting rules altogether at a slightly gentler average weight loss. Ultimately, the most effective GLP-1 is the format you take consistently alongside balanced nutrition and movement — explore your options with a licensed clinician.
References
- Wharton S, Lingvay I, et al. Oral Semaglutide 25 mg in Obesity (OASIS-4). N Engl J Med. 2025.
- Wharton S, Aronne LJ, et al. Orforglipron in Obesity (ATTAIN-1). N Engl J Med. 2025.
- Wilding JPH, et al. Once-Weekly Semaglutide in Obesity (STEP-1). N Engl J Med. 2021.
- Wharton S, et al. Once-weekly semaglutide 7.2 mg in obesity (STEP UP)00226-8/abstract). Lancet Diabetes Endocrinol. 2025.
- Jastreboff AM, et al. Tirzepatide Once Weekly for Obesity (SURMOUNT-1). N Engl J Med. 2022.
Related Clinical Guides
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.